Søren Møller joined Novo A/S in 2011 as Managing Investment Director of Novo Holdings Seed Investments.
Søren Møller obtained his MSc degree from the Technical University of Denmark in 1993 and his PhD degree in molecular biology in 1997 from the Technical University of Denmark. In addition, Søren Møller has academic training as a postdoctoral fellow at Stanford University School of Medicine.
Prior to joining Novo Holdings Seed Investments, Søren Møller served as global manager of Genomics at Novozymes. Søren Møller served as CSO and Vice President of R&D at Exiqon A/S as Exiqon completed an IPO, followed by the Company’s acquisition by Qiagen in 2016. Søren Møller previously worked in cancer drug development as head of Lead Identification at BioImage and as a research scientist at Novo Nordisk.
Since 2008, Søren Møller has been board member of Danish Biotech (the Association of Biotechnology Industries in Denmark) and DVCA (Danish Venture Capital Association).